Evolus, Inc. (NASDAQ:EOLS) Short Interest Up 8.8% in October

Evolus, Inc. (NASDAQ:EOLS) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 5,430,000 shares, an increase of 8.8% from the October 15th total of 4,990,000 shares. Based on an average trading volume of 613,400 shares, the short-interest ratio is currently 8.9 days.

Wall Street Analyst Weigh In

Several research analysts have commented on EOLS shares. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Thursday, November 7th. Barclays lifted their target price on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a report on Monday, September 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Friday, September 13th.

Evolus Stock Up 1.9 %

EOLS stock traded up $0.23 during mid-day trading on Friday, reaching $12.11. 1,167,871 shares of the company traded hands, compared to its average volume of 627,529. The stock has a market cap of $766.82 million, a price-to-earnings ratio of -13.31 and a beta of 1.31. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus has a fifty-two week low of $8.73 and a fifty-two week high of $17.82. The firm’s 50 day moving average price is $15.92 and its 200 day moving average price is $13.89.

Insiders Place Their Bets

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This trade represents a 6.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. This represents a 2.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Evolus

Hedge funds and other institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. lifted its stake in Evolus by 5,627.2% in the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after purchasing an additional 930,566 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Evolus by 24.6% in the second quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock valued at $1,965,000 after purchasing an additional 35,760 shares during the last quarter. Armistice Capital LLC purchased a new position in Evolus in the second quarter valued at approximately $3,906,000. California State Teachers Retirement System lifted its stake in Evolus by 1.6% in the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock valued at $674,000 after purchasing an additional 739 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Evolus by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock valued at $559,000 after purchasing an additional 1,637 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.